ZYBERNO
Stock Report
Updated Aug 31, 2026

ONCOLYTICS BIOTECH INC. (ONCY)

Healthcare • NASDAQ

$0.84

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
6.0/100
POOR BUSINESS
ONCOLYTICS BIOTECH INC. (ONCY) scores 6/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-605.8%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

ONCOLYTICS BIOTECH INC. (ONCY) stock report — Zyberno Score 6/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.84
Market Cap:$100.62M

Valuation Multiples (1)

Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$96.95M

Price Action & Momentum (3)

Momentum Percentile:66 / 100
% of 52-Week High:58.4%
B. Profitability Assessment

Return Metrics (3)

Reinvestment Rate:0.3%
Fundamental Growth Rate (g):-1.8%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$999.00
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:1.35x
Quick Ratio:1.35x
Cash Ratio:0.79x

Leverage Analysis (1)

Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:1,844,000.00
Cash And Cash Equivalents:4,115,000.00
Long Term Debt:$310.00K
Net Debt:-$3.67M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$28.73M

Bottom Line Performance (3)

-$28.76M
Income Before Tax:-$9.34M
Ebitda Ttm:-28,655,000.00

Operating Expenses (5)

Operating Expenses:9,379,000.00
R And D Expense:4,262,000.00
Sga Expense:5,117,000.00
Income Tax Expense:$101.00K
Interest Expense:0.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$7.67M
Current Assets:$7.07M
Ppe Net:202,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:13,838,000.00
Current Liabilities:5,225,000.00
Long Term Debt:$310.00K
Short Term Debt:$138.00K

Equity & Capital (3)

Equity:-$6.17M
Retained Earnings:-$448.18M
Common Stock:1,000,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:3,405,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:2,445,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$20.11M-$20.12M

Investment Activities (1)

Investing Cash Flow:-$6.00K

Financing Activities (3)

Financing Cash Flow:$7.61M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:7,614,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:70,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (1)

Earnings Per Share Ttm:-$0.24

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$0.17

Book Value & Capital (2)

Book Value Per Share:-$0.05
Cash Per Share:0.03

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:40.00
Quality Score:15.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:0.3%
Fundamental Growth Rate (g):-1.8%
B. Log-Linear Regression Growth Analysis
C. Company Profile & Context

Corporate Information (6)

Symbol:ONCY
Company Name:ONCOLYTICS BIOTECH INC.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:119.74M
Shares Outstanding Basic:119.74M
Shares Outstanding Diluted:119.74M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-31 18:29:02 UTC
Data Timestamp:2026-08-19T17:49:03.462742
Scroll to Top